Use the collections feature with a free QxMD account.

Use Read by QxMD to access full text via your institution or open access sources.

Read also provides personalized recommendations to keep you up to date in your field.

Existing User

New to Read

Sign up for a free QxMD account to curate your own collections of articles and to follow collections from peers around the world.

Get Started

Collections Coronary stents

Coronary stents

Follow Collection ＋

RANDOMIZED CONTROLLED TRIAL

Biolimus-eluting versus everolimus-eluting stents in coronary artery disease: a pooled analysis from the NEXT (NOBORI biolimus-eluting versus XIENCE/PROMUS everolimus-eluting stent) and COMPARE II (Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent) randomised trials.

Georgios J Vlachojannis, Serban Puricel, Masahiro Natsuaki, Takeshi Morimoto, Pieter C Smits, Takeshi Kimura

AIMS: This study sought to investigate the safety and efficacy of a biolimus-eluting stent with biodegradable polymer (BP-BES) (Nobori; Terumo Corp.) compared to an everolimus-eluting stent with durable polymer (DP-EES) (XIENCE V or Prime; Abbott Vascular, or PROMUS; Boston Scientific). METHODS AND RESULTS: The all-comers NEXT and COMPARE II clinical trials randomly assigned 5,942 patients to BP-BES (N=3,412) or DP-EES (N=2,530). We conducted a patient level pooled analysis at three-year follow-up with specified study endpoints: definite stent thrombosis (ST), the combined safety endpoint cardiac death or target vessel myocardial infarction (TV-MI), and the efficacy endpoint target lesion revascularisation (TLR)...

27802927

March 20, 2017: EuroIntervention

Make the most of Read.
Download the mobile app.

Use the collections feature with a free QxMD account.

Coronary stents

Save your favorite articles in one place with a free QxMD account.

Read

Search Tips